Forbidden Data: COVID-19 Vaccines, Cancer, and the Cost of Medical Censorship

A recent study linking COVID-19 vaccinations to reports of new or rapidly worsening cancers has ignited controversy – not only because of what it describes, but because access to the research briefly disappeared after an apparent cyberattack on the hosting medical journal’s website. While the study itself stops short of claiming definitive proof, it documents hundreds of cancer cases linked to COVID-19 vaccination across multiple countries. Taken together with years of official assurances about vaccine safety and the aggressive silencing of dissenting scientific voices, the episode exposes a growing problem: the prevalence of medical censorship in an era when corporate profits are prioritized over transparency.

The study at the center of the storm was published in early January 2026 in the peer-reviewed journal Oncotarget. Written by cancer researchers from the United States, it reviews 69 previously published medical papers and case reports from around the world. The authors identify 333 cases in which cancer was either newly diagnosed or dramatically worsened within weeks of COVID-19 vaccination. Significantly, the patients come from 27 different countries and the studies cover a five-year period – thus making it difficult to dismiss the cases as isolated flukes.

Notably, therefore, within days of the study being published, the Oncotarget website went offline. This followed a similar incident occurring on the same site the previous month. The journal blamed a cyberattack and said it would be reported to the United States Federal Bureau of Investigation (FBI). Commenting on the attack, one of the study authors, Wafik S. El-Deiry, MD, openly stated on X that: “The future is bleak if weaponized censorship in medicine continues to suppress any narratives that stand up to pharma.” The only mainstream/legacy media website to report on the attack was the UK’s Daily Mail.

Whether the outage was sabotage, coincidence, or poor cybersecurity, the effect was the same: a sensitive piece of research became suddenly hard to find. In an era when authorities repeatedly insist that they “follow the science,” science becoming inaccessible is the worst possible look.

Asking uncomfortable questions

What did the study authors actually find? Importantly, they did not conduct a new experiment. Instead, they simply reviewed what had already been publicly reported in the medical literature since 2020. Most of the papers were individual case reports where doctors describe what they have observed in specific patients. Others were much larger population studies, including one involving around 300,000 people in Italy, another covering 8.4 million people in South Korea, and a U.S. analysis of 1.3 million military service members.

Across these reports, several worrying themes emerged. Some patients developed aggressive cancers shortly after vaccination. Others saw previously slow-growing or stable cancers suddenly accelerate. In a number of cases, unusual tumor activity was found close to the vaccine injection site or nearby lymph nodes. There were also reports suggesting that vaccination may have reactivated dormant viruses known to be linked with cancer, such as the virus responsible for Kaposi’s sarcoma – a cancer that causes dark lesions on the skin, mouth, or internal organs, and a weakened immune system.

The larger population studies added to the unease. In Italy and South Korea, vaccinated groups showed higher rates of certain cancers, including thyroid, breast, lung, colon, and prostate tumors. In some analyses, people who received more doses or boosters later on showed higher rates of some cancers than those receiving fewer.

To be clear, the authors state that their review does not prove vaccines cause cancer. But this cautious wording should not be confused with reassurance. Early warning signs in medicine almost never arrive as neat, conclusive answers. They present as patterns, anomalies, and uncomfortable questions. Historically, many major drug safety scandals began with exactly this kind of ‘signal’ that was dismissed for years as coincidence.

Early warning signals are not proof – but ignoring them has consequences

What makes this situation especially troubling is the broader context. COVID-19 vaccines were rolled out at unprecedented speed, using novel technologies, under emergency authorizations. Despite this, they were promoted with extraordinary confidence. The public was told not only that they were safe, but even that serious long-term side effects were unlikely. Dissenting voices were marginalized, censored, or labeled dangerous, even when they came from qualified scientists.

At the same time, systems designed to detect harm struggled. Adverse event reporting databases were acknowledged to be incomplete. Doctors often hesitated to link serious outcomes to vaccination, fearing professional backlash. Funding flowed overwhelmingly toward promoting uptake, not investigating potential risks. Against this background, a review documenting hundreds of cancer cases linked to vaccination should have triggered intense, open investigation – not silence, ridicule, or mysterious disappearance behind a ‘502 Bad Gateway’ error.

Defenders of the COVID-19 vaccine program argue that billions of doses have been given and that cancer is common, concluding some cases will naturally follow vaccination by chance alone. That is true, up to a point. But chance does not explain repeated reports of unusually rapid progression, odd tumor behavior near injection sites, or age- and dose-related patterns appearing across multiple countries and healthcare systems. Nor does it justify the lack of transparent, independent follow-up.

Ultimately, the study’s authors themselves have called for exactly what has been missing: rigorous long-term studies, careful analysis, and transparent discussion. The fact is that vaccines are deliberately designed to stimulate the immune system. Cancer, meanwhile, is closely tied to immune balance, surveillance, and control. As such, the idea that repeated immune stimulation could, under some conditions, disturb that balance is not ‘anti-science.’ Nor either is it completely beyond the realms of possibility.

Equally important is the issue of effectiveness. COVID-19 vaccines were sold as a way out of the pandemic. Yet infections, reinfections, and ongoing transmission continued, even in heavily vaccinated populations. If the benefits are smaller and shorter-lived than promised, while potential long-term risks remain poorly understood, the risk-benefit calculation changes dramatically – especially for younger people and those at low risk from COVID-19 itself.

People were promised certainty where none existed

Whatever the cause of the Oncotarget website outage, the cyberattack narrative has become symbolic. Whether through technical failure or deliberate interference, research that challenges powerful industrial lobbies has a curious habit of sometimes becoming difficult to find. In the absence of a transparent and credible explanation, this can erode trust far more than any controversial finding ever could. Science advances through open debate, replication, and criticism – not through silence and control.

None of this means that every cancer diagnosis after COVID-19 vaccination was caused by the injection itself. But it does mean that the public was promised certainty where none existed. It also means that legitimate safety signals may have been brushed aside in the rush to maintain confidence, and that institutions charged with protecting public health may have become more invested in defending decisions than in questioning them.

For a truly health-centered approach, the response should be simple: full transparency, unrestricted access to data, and independent investigation free from political or commercial pressure. Anything less is not science – it is marketing. When it comes to medical interventions given to billions of people, often coercively, the burden of proof should always rest on those claiming safety – not on those asking inconvenient questions.